I N T RO D U C T I O N
The rapid evolution of genomic technologies and clinical phenotyping provides unprecedented opportunities to discover the genomic factors and underlying biological pathways that drive chronic kidney disease (CKD). Recent discoveries that are ushering in the era of personalized medicine for treatment and kidney transplantation are the fruits of decades of investments in sample collection and careful disease characterization.
Choosing the appropriate phenotype remains critical to detecting nephropathy susceptibility genes. Cases with similar clinical courses and homogeneous renal histology are optimal. However, the majority of studies lack kidney tissue. Therefore, patients with end-stage kidney disease (ESKD) or markedly reduced estimated glomerular filtration rates (eGFRs) are valuable for defining severe disease. Albuminuria can be a marker of subclinical kidney disease; however, levels fluctuate widely, and low levels better reflect cardiovascular risk. It is probable that different genomic regions underlie susceptibility to nephropathy initiation, progression and albuminuria. Here, we review the state of genetic epidemiology of non-Mendelian forms of CKD. In doing so, we highlight illustrative conceptual examples and provide lists of the primary genomic findings to date.
CANDIDATE GENE STUDIES
Candidate gene studies dominated the field 15 years ago due to the existing state of technology and their more modest costs. In contrast to the agnostic or unbiased genome-wide association study (GWAS) approach, candidate gene studies are hypothesis driven and leverage external knowledge sources to motivate investigation of specific polymorphisms, genes or biological pathways. The positional cloning paradigm was one of the major motivators for candidate genes. Here, a linkage signal identified a genomic region that cosegregated with a trait and polymorphisms and candidate genes within the region were genotyped and tested for association. The success of this approach was limited by the feasibility of densely genotyping regions and our lack of knowledge about the genes themselves and their respective biological pathways. However, the advent of next-generation sequencing technologies and the impressive evolution in the annotation of the human genome make candidate gene studies increasingly attractive.
There are several informative examples of candidate gene studies in CKD. Böger et al. [1] investigated 16 loci previously associated with eGFR for association with incident CKD and ESKD in European-ancestry populations. Although 11 of the 16 single-nucleotide polymorphisms (SNPs) were associated with CKD, there was minimal evidence of an ESKD association. Parsa et al. [2] leveraged GWAS data to test for associations between eGFR and common variants in 258 Mendelian renal dysfunction genes; none of the novel 49 loci that passed gene-specific Bonferroni correction thresholds in the discovery set replicated. Although this study failed to link novel genes to eGFR, the design is illustrative and the study informative.
L I N K A G E A N A LY S I S
Linkage analyses employ family-based data [ranging from large multigenerational pedigrees to affected (or discordant) sibling pairs] to test coinheritance of disease with genetic markers. Recruitment is typically more difficult than for association studies that contain unrelated individuals. Large-scale, genome-wide linkage studies have not efficiently identified robust, replicated genes for non-Mendelian renal disease, although linkage between the carnosinase gene (CNDP1) and diabetic kidney disease (DKD) was described [3] . Even large-scale meta-analyses of kidney function (i.e. eGFR, albuminuria, serum creatinine concentration, creatinine clearance) across 14 studies failed to detect genome-wide linkage signals [4] . These authors suggest that heterogeneity across populations, methodology and study design or an inherent inefficiency of the linkage methodologies contribute to the lack of robust findings. Few linkage signals have been successfully mapped to a responsible association and functional polymorphism. However, family-specific linkage analysis and two-point linkage using dense genotyping, such as next-generation sequencing, may still prove valuable for rare variants of large effect.
M A P P I N G B Y A D M I X T U R E L I N K A G E D I S E Q U I L I B R I U M
Genetic differentiation among ancestral groups occurs through the influences of bottlenecks, natural selection and genetic drift. Recent admixture among populations generates long-range linkage disequilibrium (LD). If disease-predisposing alleles and trait prevalence rates differ in the ancestral groups that comprised the recently admixed population, these differences and the long-range LD can be leveraged to identify allelic associations. The apolipoprotein L1 gene (APOL1) and nondiabetic etiologies of CKD are prime examples. Individuals who possess recent African ancestry, relative to European, have markedly higher rates of CKD; the APOL1 G1 and G2 renal risk variants are nearly exclusively present in individuals with recent African ancestry, including African Americans.
Familial clustering of ESKD is most pronounced in African Americans; >30% of incident African Americans on dialysis had relatives with ESKD. In contrast to other ethnic groups, multiple etiologies of ESKD frequently aggregate within these families [5] . Admixture mapping in African Americans with idiopathic focal segmental glomerulosclerosis (FSGS) and nondiabetic ESKD (versus controls) revealed excess African ancestry on chromosome 22q; APOL1 G1 and G2 renal risk variants were subsequently identified as causative [6] [7] [8] . Inheriting two APOL1 renal risk variants (autosomal recessive) is associated with a broad spectrum of non-DKDs, including FSGS, HIV-associated nephropathy (HIVAN), focal global glomerulosclerosis with interstitial and vascular changes (incorrectly attributed to the effects of essential hypertension in the past), severe lupus nephritis, sickle cell nephropathy and shorter allograft survival in transplanted kidneys from African American deceased donors [9] . APOL1 is among the most powerful genetic causes of complex disease, and its variation explains the majority of excess risk for nondiabetic ESKD in African Americans relative to European Americans and contributes to 70% of cases of FSGS and HIVAN in African Americans. APOL1 renal risk variants recently appeared in sub-Saharan Africa (∼10 000 years ago), selected for due to the protection they afford from the parasite that causes African sleeping sickness.
G E N O M E -W I D E A S S O C I AT I O N S T U D I E S
The past decade has seen a remarkable transition from linkage studies under family designs (e.g. affected relative pair) to GWASs. As predicted by Risch and Merikangas [10] and others, this transition has led to an unprecedented number of robust statistical associations for complex genetic disorders, including CKD. In brief, GWASs include genotyping 100 000 to millions of genetic markers, such as SNPs, across the genome and testing for association between the markers and phenotypes (e.g. cases with ESKD versus nonnephropathy controls, or eGFR). The fundamental principle that motivates GWASs is the correlation among alleles at different loci in close physical proximity (LD), allowing a subset of genetic markers to 'tag' markers in LD. Importantly, the physical distance that exhibits significant LD or correlation among markers varies across the genome and across ancestral backgrounds (e.g. races). Transancestral mapping can leverage different LD patterns across ancestral groups to more sharply localize the association. The GWAS approach is effective in a wide range of study designs (e.g. unrelated individuals, pedigrees, discordant sibling pairs, parent-affected offspring trios). However, study ascertainment should be considered in the analysis strategy. It is important to recognize that statistical association does not imply that a specific polymorphism is functional relative to the disease or trait. Rather, the hypothesis is that it is in close proximity to a functional polymorphism. GWASs typically identify common variants with mild impacts on risk of disease. Shimazaki et al. [11] and Maeda et al. [12] performed an early GWAS for DKD in Japanese cases and controls with only 80 000 gene-based SNPs prior to HapMap. This landmark work identified the association of DKD with ELMO1, ACACB, SLC12A3 and NCALD; replicated in several additional studies in DKD.
The GWAS Catalog is a joint effort of the National Human Genome Research Institute (NHGRI) and the European Bioinformatics Institute (EMBL-EBI) that curates GWASs to generate a dataset of SNP associations with P-values <1.0 × 10 −5 . Querying the GWAS Catalog for CKD and related phenotypes (ESKD, eGFR, DKD, IgA glomerulonephritis) resulted in 132 SNP associations from 18 studies ( Table 1 ). The 132 SNP associations correspond to 55 unique chromosomal positions, with the most frequent locations being [region (count)]: 6p21 (26), 16p12 (9), 4q21 (7), 15q21 (7), 11p14 (4), 2p13 (5), 17q23 (5) and 22q12 (5) . The remaining regions exhibited three or more representations within the GWAS Catalog entries [with a majority of replications in the same study, for different phenotype(s) or model(s)]. Many journals require integration of replication datasets or functional work in support of an association. Despite these requirements, there is limited replication of results across studies, and particularly limited replication across ethnicities. Associations involved with DKD largely appear independent of those for nondiabetic nephropathy. Here, we highlight the most robustly replicated associations in CKD.
While 6p21 was the most frequently associated region within the GWAS Catalog for CKD and related traits, there was little overlap of reported genes. This region corresponds to the major histocompatibility complex (MHC) on chromosome 6, the most polymorphic region in the genome. The MHC exhibits high degrees of LD, which will likely increase the chances of replication but similarly increase the difficulty to refine associations to a particular locus. For example, Okada et al. [13] broadly linked their associations to the entire region (MHC). The majority of the 6p21 associations came from a study of membranous glomerulonephritis in individuals of European ancestry [21] . Other sources of 6p21 associations were IgA nephropathy in Han Chinese [20, 22] .
The uromodulin gene (UMOD) on 16p12 is among the most replicated genes in the GWAS Catalog for CKD and related phenotypes. UMOD encodes a protein that may act as a constitutive inhibitor of calcium crystallization in urine and serve as a defense against urinary tract infections [23] . In European populations [14, 15, 24] , rs12917707 (intergenic, upstream of PDILT and UMOD) is the most strongly associated SNP, whereas rs11864909 located in PDILT topped the list in an Asian population [13] . Surprisingly, these SNPs are not in LD in European or Asian populations (r 2 < 0.02 in both). This GWAS association was interesting because UMOD had been implicated in autosomal dominant tubulointerstitial kidney diseases such as medullary cystic kidney disease type 2, glomerulocystic kidney disease with hyperuricemia and isosthenuria and familial juvenile hyperuricemic nephropathy [25] . In the aforementioned study of Mendelian kidney disease genes [2] , the UMOD association for rs12922822 provides replication for rs12917707 in European ancestry populations (r 2 = 1.0). For a candidate gene study in African ancestry populations, UMOD SNP rs4293393 (in perfect LD with rs12917707 in Europeans) was nominally significant with CKD [26] .
Each of the seven GWAS-identified 4q21 associations subsequently mapped to the shroom family member 3 gene (SHROOM3), which encodes a PDZ domain-containing protein that may be involved in regulating cell shape in specific tissues [27] . Relative to kidney disease, the association was first identified by Kottgen et al. [15] in a European ancestral cohort for eGFR. A follow-up study with a larger cohort [14] replicated this association for eGFR, but detected no association with CKD. SHROOM3 is one of a few CKD genes that exhibit replication in both European [17, 19] and Asian [13] ancestries. Although these associations mapped the gene to kidney functional traits such as serum creatinine concentration and eGFR, there had not been strong associations with incident CKD [1] . Yeo et al. [27] reported an association with prevalent ESKD in African Americans. The seven GWAS associations in SHROOM3 map to five unique SNPs that are in high LD in both European and East Asian ancestries and are likely tagging the same association. Testing additional SHROOM3 SNPs for association with eGFR in a cohort with recent African ancestry revealed a suggestive association [26] .
Further support for these and other associations come from meta-analyses across studies. Larger sample numbers provide greater statistical power to identify novel associations and posit critical biological pathways, as illustrated by Pattaro et al. [28] . With >130 000 individuals and a replication dataset exceeding 40 000, 24 novel associations were identified with eGFR and 29 previously established loci replicated. SNP annotations such as DNase I hypersensitivity analyses suggested that the functionality of these SNPs appears specific to renal tissues. Transancestral meta-analysis (i.e. samples from different ancestral backgrounds) such as the Family Investigation of Nephropathy and Diabetes (FIND; comprised of European American, African American, Mexican American and Native American ancestries) [18] may be able to leverage differences in LD in diverse ancestral backgrounds to further localize associations.
The large sample sizes in population-based collaborations for eGFR finally provide the opportunity to complete appropriately powered gene-gene and gene-environment interactions for renal traits. It is yet to be determined how much such interactions contribute to the risk of ESKD, but intriguing results exist [29] .
G E N E E X P R E S S I O N S T U D I E S
RNA gene expression studies quantify the amount of RNA in a sample. Gene expression varies within an organism by cell type and over time and is controlled in part by epigenetic factors. Of published gene expression studies directly relevant to CKD, few evaluated expression profiles across the genome. Instead, most evaluated gene expression at or near loci of interest (e.g. SNP association). For renal-related gene expression studies, Nephroseq (nephroseq.org) is the most comprehensive resource of publically available data (26 datasets). Here, users can search for specific gene expression patterns across phenotypes. This resource offers tools for both visualizations and analyses across studies.
Age-related gene expression patterns were investigated within the renal cortex and medulla [30] . Many of the 985 age-related genes correlated with overall kidney health. Of Table 1 . CKD and related associations from the GWAS Catalog with P-value <1E−6 note, none of the most frequently associated loci from the GWAS Catalog were identified by this study. Ledo et al. [36] predicted that previously identified SNP associations influenced transcript binding sites. Using RNA sequencing in both tubule and glomerular samples, genes were evaluated around CKD-associated SNPs (226 transcripts surrounding 40 SNPs). In several cases, multiple genes around a particular SNP were found to have expression levels associated with eGFR or CKD, resulting in newly implicated genes. These results underscore the importance of functional studies and recognize that SNPs may be tagging functional genes other than the closest gene. A SNP whose genotype is correlated with gene expression is known as an expression quantitative trait locus (eQTL). A disease-associated SNP that is also an eQTL adds functional context to associations. Searching for strong eQTLs can link association to genes and help in identifying causal variants among noncausal variants in LD.
Wheeler et al. [37] performed an eQTL analysis for agerelated genes within healthy kidney tissues. Of the 630 genes that were correlated with kidney age, 101 contained eQTLs. However, only one eQTL (rs1711437; MMP20) was associated with eGFR (P = 3.6 × 10
), a result that has yet to be replicated. Menon et al. [38] found that donor genotypes at rs17319721 in SHROOM3 (known to be associated with CKD) correlated with SHROOM3 gene expression in renal allografts of patients with chronic allograft nephropathy. Increased expression correlated with increased allograft fibrosis and reduced kidney function.
There are many publically available resources that provide eQTL annotations for SNPs. The Broad Institute's GTEx summarizes not only expression patterns across genes, but also eQTLs in a variety of tissue samples [39] . Kottgen et al. [14] and Pattaro et al. [16] leveraged existing eQTL data to add functional annotation to GWAS associations. Of the 23 loci identified in Kottgen et al., 11 had at least one eQTL SNP within LD of their top association. Of the six significant loci from Pattero et al., only rs12124078 was found to have an eQTL (CASP9 gene in myocytes). Utilizing GTEx, we searched for eQTLs within the 112 unique CKD GWAS SNPs and found 49 variants were an eQTL for at least one gene in at least one tissue.
D N A M E T H Y L AT I O N
DNA methylation is a type of epigenetic modification through the covalent addition of a methyl group, thus the original DNA sequence remains unchanged. While methylation has been observed across other nucleotides [40] , the methylation of cytosine's 5 0 carbon is the most common and most widely studied. The potential for cytosine methylation occurs when the base is adjacent to a guanine residue in the 5 0 to 3 0 direction. These positions of potential methylation are termed 'CpG' (cytosine-phosphate-guanine) sites to emphasize the juxtaposition of these bases along the same strand. Epigenetics parallel genetic association studies in examining candidate regions using pyrosequencing or genome-wide agnostic scans using methylation arrays and bisulfite sequencing.
Methylation levels across the genome are tissue specific and are influenced by many factors, including, age, gender and environmental factors such as diet, physical activity and therapeutics [41] . The influence of CpG methylation on gene expression is well established [42] . Studying DNA methylation has the potential to provide insights into disease and treatments. In the case of CKD, DNA methylation has the potential to uncover some of the missing heritability that is currently unexplained by DNA variation. Additionally, since CKD risk and progression have been tied to environmental conditions such as 'metabolic memory' with hyperglycemia [43] and prenatal programming [44] , epigenetic mechanisms are likely implicated.
Associations with DNA methylation and CKD phenotypes have added functional insights into existing gene association and expression studies. Genome-wide methylation studies (Table 2) , such as the 2014 Smyth study [45] , have identified ELMO1, PRKAG2, CUX1 and PTPRN2, all previously implicated with CKD phenotypes, either through SNP associations [14, 46] or differential gene expression [11] .
In promoter regions, hypermethylation tends to correlate with decreased gene expression; cancer cells have been shown to exploit DNA methylation to silence genes, such as tumor suppressors [47] . Decreased expression of KLOTHO, whose protein is a coreceptor of fibroblast growth factor 23 (FGF23), has been correlated with the severity of CKD in rodent and human studies [48, 49] . Epigenetic investigation of this established CKD gene found promoter Klotho methylation correlated with gene silencing within renal tubules of mice [50] . The negative correlation between KLOTHO expression and KLOTHO methylation was replicated in human renal tissue from 48 patients with renal cell carcinoma and 47 patients with CKD [51] . Within the CKD patients, negative correlations between KLOTHO promoter methylation and eGFR were also observed. In vitro analysis, using human renal tubule cells, yielded evidence that changes in methylation could be induced by uremic toxins such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS) [50] .
DNA methylation can also implicate novel genes, particularly for CpG sites that are not in LD with any previously disease-associated SNPs. Due to the numerous influences on DNA methylation, studies must be carefully designed (e.g. gender-and age-matched) to ensure associations reflect the phenotype of interest. While studies have found significant results from whole blood methylation studies [45, 52] , there are potential confounders. For example, do the differences in blood methylation patterns reflect differing cell populations between individuals who have healthy kidneys versus those with CKD? Although de-convolution methods exist, disease-relevant tissue is the gold standard to which whole blood or its constituents must robustly correlate. If blood-based markers correlate with disease-relevant tissue, they are of great importance when considering practical biomarkers for potential diagnoses.
Ko et al. [53] leveraged the tissue specificity of methylation by evaluating differences in tubule epithelial samples between CKD patients and healthy controls. In their discovery and replication cohorts, the majority of differentially methylated regions (DMRs) existed outside of gene promoter regions. Investigating the motifs surrounding these DMRs revealed enrichment for kidney-specific enhancer regions and transcription binding sites. The functional impact of these sites was supported through the correspondence of independently tested transcription levels for genes. A subset of the methylation results from Ko et al. [45] was replicated using whole blood in an independent sample. Linking expression levels to specific molecular mechanisms, such as DNA methylation, is crucial for both drug therapeutics (development and response) and CKD diagnostic biomarkers. For researchers interested in whether specific CKD variants or genes may be influenced by methylation, there are many resources that have compiled existing methylation information across a number of tissues (Table 3) . DeepBlue, by the Max Planck Institute for Informatics, compiles information across many of the primary epigenetic resources, including ENCODE, NIH Roadmap Epigenomics Mapping Consortium, BLUE-PRINT Epigenome Project and German Epigenome Programme [54] .
F U T U R E / CO N C L U S I O N S
The rapid evolution of genomic technologies has enabled the discovery of important genomic markers (e.g. SNP association, differential gene expression, DMRs) that correlate with CKD. However, the rate of progress will always be dependent on robust and informative phenotyping in cohorts of sufficient sample size to be well powered for the specific hypothesis.
Genomic associations with CKD and CKD-related traits have translational impact potential. Candidate gene, mapping by admixture linkage disequilibrium and GWAS have identified a number of SNP associations; however, the majority lack robust corroborating evidence in independent studies. In strong contrast are the robust and informative associations implicating SHROOM3, UMOD and APOL1. Subsequent research on these genes underscores the potential translational impact of these associations on understanding ethnic differences in disease rates and survival, renal allograft survival and age at onset of ESKD. For example, Klotho is a coreceptor for FGF23, and decreased expression has long been associated with the severity of CKD. 1,25-dihydroxyvitamin D increases Klotho levels. Klotho hypermethylation was recently found to be associated with both Klotho expression and CKD severity (renal fibrosis). In vitro studies show that increased DNA methyltransferase expression and DNA hypermethylation were regulated by uremic toxins [50] . The limited numbers of published methylation studies motivate an intriguing hypothesis that other genes influencing CKD are under epigenetic influence.
Next-generation sequencing technologies in cell populations or individual cells will expand our understanding of the influence genomic factors have on CKD. Thoughtfully, integrating these powerful genomic technologies with metabolomic data should further delineate key relationships. However, the success of genetic epidemiology and genomics in CKD will remain critically dependent on informative and high-quality phenotype data. Thus, teamwork between geneticists and the clinicians who treat patients with CKD remains important for future success.
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